Pall Life Sciences launches commercial Cadence Acoustic Separator for intensified bioprocess clarification and purification applications
The commercial launch of the CAS is the first in a series of product launches that enable continuous bioprocessing.
Pall Life Sciences Biopharmaceutical has announced the commercial launch of the Cadence Acoustic Separator (CAS), which applies acoustic wave separation technology in a novel single-use format for the clarification of cell culture bioprocess fluids. The CAS delivers robust, reliable cell and protein yields in a closed system without centrifugation, while drastically reducing user cost and risk. The CAS has been designed to be easily integrated with other Pall Life Sciences products to enable continuous bioprocessing.
“We launched our continuous processing vision at the end of 2015, introducing the concept of acoustic wave separation technology as an enabling tool for customers to bridge the critical gap between the bioreactor and the downstream processing train. We have now brought that concept to fruition with the commercial launch of the CAS as the first in a series of product launches that enable continuous bioprocessing,” said Vice President and General Manager of Biopharmaceuticals, Michael Egholm. “The CAS technology is truly revolutionary, eliminating reliance on centrifugation for cell culture clarification, reducing buffer requirements by around 75%, and creating a continuous feed stream for direct integration with our full portfolio.”
Pall Life Sciences obtained an exclusive license to acoustic wave separation technology in June 2015 from FloDesign Sonics. The CAS works via acoustic forces that are applied across a countercurrent flow of bioprocess fluid, generating three-dimensional standing waves that trap cells at their nodes. This leads to aggregation and precipitation from suspension, thereby “trapping” the cells for simple extraction. The CAS is capable of clarifying many types of biologic products, including recombinant therapeutic proteins and monoclonal antibodies, regardless of the variability in particulate concentrations and cell culture density, turbidity and viability.
The CAS is part of the Cadence product portfolio, which features enabling technologies for key unit operations required in the continuous production of monoclonal antibodies and other recombinant proteins. The Cadence portfolio leverages the benefits of single-use technologies to feature integrated, end to end biomanufacturing solutions that increase productivity and decrease risk for customers.
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance